Targeting GERD Complications in Older Patients: An Educational Update for Pharmacists

If you cannot view the webcast, click here to download the free Flash Player.

Sponsored by Princeton CME

Target Audience

This activity is designed for clinical and managed markets pharmacists.

Learning Objectives

After completing this activity, participants should be able to:

Define gastroesophageal reflux disease (GERD) as a lifelong condition with the potential for severe progression and complications
Explain the potential differences in GERD manifestations in older versus younger patients, including atypical symptoms and treatment challenges associated with GERD in the older population
Summarize the risk/benefit profiles of GERD management approaches, including lifestyle modifications, surgery, and medications
Implement current evidence-based GERD diagnosis and management approaches into pharmacy practice to minimize GERD progression and complications and reduce the clinical and cost burden of disease

Credit Eligibility

To be eligible for documentation of credit, individuals must participate in the full educational activity, complete the 10-question post-test with a score of 70% or better, and complete the evaluation form. Participants who successfully complete the post-test and evaluation form online may immediately print their documentation of credit.

Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.

Release Date: August 23, 2007; Expiration Date: August 23, 2008

Estimated time to complete: 1 hour

There is no fee associated with this activity.

CPE Accreditation

Princeton CME is accredited by the Accreditation Council for Pharmacy Education as a Provider of continuing pharmacy education (ACPE Provider #452) and complies with the Criteria for Quality and Interpretive Guidelines. This activity is approved for 1 hour credit (0.1 CEU) of continuing pharmacy education (ACPE #452-000-07-025-H01).

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity sponsored or cosponsored by Princeton CME may contact the Assistant Director of Continuing Education in writing. The Assistant Director of Continuing Education will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Director of Continuing Education may be made for a second level of review.

Grant Support

Supported by an educational grant from Wyeth Pharmaceuticals

Presenters

Randolph V. Fugit, PharmD, BCPS
Internal Medicine Clinical Specialist
Denver Veterans Affairs Medical Center
Adjoint Assistant Professor, Pharmacy Practice
University of Colorado Health Sciences Center
Denver, Colorado

Brien L. Neudeck, PharmD
Associate Professor of Clinical Pharmacy
University of Tennessee
College of Pharmacy
Memphis, Tennessee

Independent Clinical Reviewer

John W. Devlin, PharmD, BCPS, FCCM, FCCP
Associate Professor
Department of Pharmacy Practice
Northeastern University School of Pharmacy
Adjunct Associate Professor
Tufts University School of Medicine
Clinical Pharmacist Medical Intensive Care Unit
Tufts-New England Medical Center
Boston, Massachusetts

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of Princeton CME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of Princeton CME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:

Dr. Devlin: Speaker—Hospira; Consultant—Eli Lilly and Company, Hospira, The Medicines Company; Research funding—AstraZeneca (principal investigator; funds paid to Tufts-New England Medical Center), Hospira (principal investigator; funds paid to Northeastern University), TAP Pharmaceuticals (principal investigator; funds paid to Northeastern University)

Dr. Fugit: Speaker and Consultant—Boehringer Ingelheim, Cubist, Elan, Pfizer, sanofi-aventis U.S., TAP Pharmaceuticals; Research funding—Pfizer (principal investigator; funds paid to the VA Research Fund)

Dr. Neudeck: Speaker and Consultant—Wyeth Pharmaceuticals; Research funding—Wyeth Pharmaceuticals

Planning Committee Randy Robbin and John Savage, Princeton CME; Kristin Dickie and Mary Johnson, Princeton Media Associates have disclosed no relevant financial relationships with any commercial interests.

Princeton CME requires faculty to inform participants whenever off-label/unapproved uses of drugs or devices are discussed in their presentation.

The faculty has disclosed that the following off-label/unapproved uses of drugs or devices will be discussed: GERD diagnosis with proton pump inhibitors in patients with noncardiac chest pain.